

Simultaneous determination of 5 diuretic drugs using an HPLC method by quantitative analysis of multiple components by a single marker

Fuchao Chen

Hubei University of Medicine

Baoxia Fang

Hubei University of Medicine

Peng Li (✉ dfyylp@163.com)

Hubei University of Medicine

Sicen Wang

Xi'an Jiaotong University

Research Article

Keywords: Diuretic drug, Multi-components detection with a single marker, HPLC, Method development

Posted Date: April 8th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-397940/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Simultaneous determination of 5 diuretic drugs using an HPLC method by quantitative analysis of multiple components by a single marker

Fuchao Chen ¹, Baoxia Fang ¹, Peng Li ^{1*}, and Sicen Wang ^{2*}

1 Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei, 442008, P.R. China. 2 School of Pharmacy, Xi'an Jiaotong University, Xi'an, 710061, Shanxi, PR China.

Fu-chao Chen and Baoxia Fang contributed equally to this work and should be considered as equal first authors.

Correspondence to: Peng Li, E-mail: dfyylp@163.com. Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei, 442008, P.R. China. Sicen Wang, E-mail: wangsc@mail.xjtu.edu.cn. School of Pharmacy, Xi'an Jiaotong University, Xi'an, 710061, Shanxi, PR China.

Abstract:

Background: Loop diuretics are commonly used in clinical practice to manage high fluid loads and to control fluid balance. In this paper, a novel quantitative analysis method for multiple components with a single marker (QAMS) was developed for the simultaneous determination of 5 diuretic drugs furosemide, torasemide, azosemide, etacrynic acid, and bumetanide, by HPLC. Qualitative analysis was performed using relative retention time and ultraviolet (UV) spectral similarity as the double indicator. The QAMS method was conducted with etacrynic acid as an internal reference substance. The quantities of the other four diuretics were calculated by using the relative correction factors for etacrynic acid. The quantities of the 5 diuretic drugs were also determined by the external standard method (ESM). Chromatographic separation was achieved on a Shimadzu HC-C₁₈ column (150 mm× 4.6 mm, 5µm) using 50 mM potassium dihydrogen phosphate (pH adjusted to 4.0 with phosphoric acid) with acetonitrile (64:36, v/v) as the mobile phase at a flow rate of 1.0 mL/min and a column temperature of 30 °C.

Results: Under these conditions, the 5 diuretic drugs were well separated, showing linear relationships within certain ranges. The quantitative results showed that there was no significant difference between the QAMS and ESM methods.

Conclusions: Overall, the HPLC-QAMS analytical scheme established in this study is a simple, efficient, economical, and accurate method for the quantitative evaluation of 5 diuretic drugs.

Keywords: Diuretic drug; Multi-components detection with a single marker; HPLC; Method development

Introduction

Loop diuretics (LDs) are a kind of drug prescribed widely in clinical practices to manage the high fluid load and to control fluid balance [1]. The pharmacologic action of LDs, blocks the $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter, which transfusions from the tubular lumen into tubular cells. They inhibit Na^+ and Cl^- reabsorption in the thick ascending limb of the loop of Henle and cause increased secretion of water, K^+ , Na^+ , and Cl^- [2]. Furosemide, torasemide, azosemide, bumetanide, and etacrynic acid are examples of this class of diuretics [3].

Furosemide (Fig 1a), a 5-sulfamoylbenzoic acid derivative LD, has been the most widely prescribed with regard to administration via continuous infusion, and the chemical name is 5-(aminosulfonyl)-4-chloro-2-([2-furanylmethyl]amino)benzoic acid [4]. Torasemide (Fig 1b), a nonacidic LD, has a long half-life, long time of action, and higher bioavailability than the other LDs, and its chemical name is 1-[4-(3-methylphenyl)aminopyridine-3-based]sulfonyl-3-isopropylurea [5]. Azosemide (Fig 1c), [2-chloro-5-(1H-tetrazole-5-yl)-N4-(2-thenyl)sulfanilamide], is a sulfonamide LD, that is used clinically in the treatment of oedema of various geneses and hypertension [6]. Bumetanide (Fig 1d), a 5-sulfamoylbenzoic acid derivative LD, has the chemical name 3-(aminosulfonyl)-5-(butylamino)-4- phenoxybenzoic acid [7]. Etacrynic acid (Fig 1e), [2,3-dichloro-4-(2-methyl- enebutyryl)phenoxy)-acetic acid], is chemically different from all other known diuretic agents, and is now mainly used for patients with severe sulfonamide allergies that prohibit the use of other LDs [8].

Currently, several analytical methods have been reported by HPLC for the quantification of furosemide, torasemide, azosemide, bumetanide, or etacrynic acid either alone or in combination with other drugs, both in their prescribed forms and in biological fluids [9-21]. The abovementioned methods, however, have not been employed for the simultaneous quantification of the five LDs in any pharmaceutical formulation. The QAMS method is able to simultaneously determine the concentrations of multiple components by a single reference standard, which greatly reduces the cost and reduction of the analysis time of the experiment [22-29]. Thus, the present study developed a rapid HPLC-QAMS method for the determination of the five LDs. The developed QAMS method was evaluated by comparing the calculated results with an external standard method (ESM) method. This method was

then successfully applied for the quality evaluation of formulas of the five LDs in hospitals.

Experimental

Materials and reagents

Five reference substances (furosemide, torasemide, azosemide, bumetanide, and etacrynic acid) were obtained from the National Institutes for Food and Drug Control (Beijing, China). The purity of each of the five reference substances was higher than 99%. Chromatographic grade methanol and acetonitrile were purchased from Kemiou Chemical Reagent Co., Ltd. (Tianjin, China). AR grade of potassium dihydrogen phosphate (KH_2PO_4), triethylamine, and phosphoric acid were obtained from Sinopharm Chemical, Shanghai, China. Pharmaceutical formulations containing furosemide, torasemide, azosemide, bumetanide, or etacrynic acid were obtained commercially.

Apparatus and analytical conditions.

Chromatographic separations were achieved on an Agilent HPLC 1260 system equipped with a diode array detector (G4212B), autosampler (G1329B), quaternary pump (G1311C), and column oven (G1316A). A digital workstation with ChemStation software Version C.01.10 served as both a controller and data manager for the overall system. A Shimadzu HC-C₁₈ column (150 mm×4.6 mm, 5 μm) was applied during the study under the following analytical conditions: the mobile phase was composed of acetonitrile with 0.05 mol/L KH_2PO_4 (pH adjusted to 4.0 using diluted phosphoric acid) (36: 64, v/v) at detection wavelengths of 260 nm and 278 nm, at a flow rate of 1.0 mL/min. The column temperature was retained at 30°C, and a sample volume of 20 μL was injected by an automatic sampler.

Laboratory prepared mixture standard solution.

Furosemide, torasemide, azosemide, bumetanide, and etacrynic acid references were weighed precisely to 25.0 mg each, and then the compounds were dissolved in the mobile phase in a 50 mL volumetric flasks. These stock standard solutions were stored at 4°C and warmed to room temperature before use. Mixed working solutions of the five LDs were prepared, and the mobile phase was added to form a mixed

reference solution with a concentration of **approximately 50 µg/mL** of the reference substance.

Method Validation

The method was validated according to the International Conference of Harmonization (ICH) guidelines [30]. The following parameters were investigated: **linearity, precision, stability, accuracy, limit of detection and robustness.**

Linearity and range

The linearity and range of the method were evaluated with the standard solution of the five LDs at six different concentrations. The concentrations ranged from 2.5 to 150.0 µg/ml for the five LDs, respectively. The mixed test working standard solutions were prepared by appropriate dilution of the stock solutions with mobile phase to the required concentrations for plotting the calibration curves. A 20 µL aliquot of each working solution was injected in triplicate into the chromatographic system (n=3). The standard curves of the five LDs were constructed from the different concentrations of the mixed solution. Chromatograms were recorded, and the standard calibration curve was generated with peak area as the Y-axis (Y) and the concentration (µg/mL) of each standard solution as the X-axis (X).

Precision

The mixed standard solution at the same concentration was continuously injected six times **on the same day or on different days** according to the chromatographic conditions described in Section **analytical conditions**. The relative standard deviation (RSD) values were evaluated by the chromatographic peak area of the five LDs.

Stability

The same mixed working standard solutions **were** injected into **the** HPLC at 0 h, 2 h, 4 h, 6 h and 8 h with the same mobile phase. The **RSDs** of the five peaks areas were determined.

Recovery

The accuracy of the assay method was calculated in triplicate by adding known amounts of the five **LD** reference **substances** to commercial **sample** solutions. Each

solution was prepared at three concentrations (i.e., 40, 50, and 60 µg/mL), and each solution was injected into HPLC in triplicate. Then, the peak areas were recorded, and the average recovery, and RSD % of each LD were calculated.

Robustness

The robustness study was conducted by examining the samples on three different HPLC instruments: a Dionex U3000, an Agilent 1260 series, and a Shimadzu LC-20A. Three different models of chromatographic columns were used, including an Agilent Zorbax Extend C₁₈, Shimadzu HC-C₁₈ column, and Kromasil C₁₈ (150 mm×4.6 mm, 5 µm). The samples were determined to have various pH values (3.8, 4.0, 4.2), flow rates of the mobile phase (0.98 mL/min, 1.0 mL/min, and 1.02 mL/min) and column temperatures (29°C, 30°C, and 31°C). The separation degree and %RSD of the five LDs were investigated.

Qualitative investigation.

UV spectral similarity.

The mixed standard solutions of five LDs were injected into HPLC under the above analytical conditions. The chromatogram maps and UV spectra were recorded, and the similarity of the original and first-order spectra of the five LDs was analysed by the ChemStation software Version C.01.10.

Relative retention time.

Under the analytical conditions described in sections analytical conditions and robustness, the same standard solutions of the five LD mixtures were tested and peak retention times were recorded to determine the relative retention time (RRT). The RRT is calculated by the following formulae [1]:

$$RRT = (t_A - t_0) / (t_R - t_0) \quad [1]$$

where t_0 , t_R and t_A represent the retention times of urine pyrimidine, etacrynic acid, and analyte, respectively.

Quantitative Analysis of Multiple Components by a Single Marker (QAMS)

The application of the QAMS method in the quality control of the five diuretic drugs was based on the relative correction factor (RCF) of each component, which is

proportional to the detection signal in a certain concentration range. In this study, we selected **etacrynic acid** as the internal standard, and used equation (2) to calculate the **RCF** of **the** other diuretics.

$$\text{RCF} = \frac{\text{RCF}_s}{\text{RCF}_i} = \frac{A_s / C_s}{A_i / C_i} \quad (2)$$

where A_s is the peak area of **the** internal standard (etacrynic acid), C_s is the concentration of **the** internal standard (etacrynic acid), A_i is the peak area of other investigated components i , and C_i is the concentration of other investigated component i in the sample solution.

From the equation (2), we can derive the equation (3)

$$C_i = \text{RCF} \times C_s \times \frac{A_i}{A_s} \quad (3)$$

We can **use** equation (3) to calculate the concentration of **each component** of the sample solution. **Additionally**, the effects of **the** different HPLC systems, **the** pH of **the** mobile phase, **the** gradient elution scheme, **the** flow rate, **the** injection volume and **the** column temperature given **in** section **robustness** for **the RCF** were investigated.

Analysis of the five LDs in commercial injections

To determine the content of furosemide, bumetanide, and torasemide, commercially available injections of the 3 diuretics were prepared with **the** mobile phase. To determine the content of azosemide and etacrynic acid in conventional tablets, ten tablets were weighed, and disintegrated by shaking for 1 min with 10 mL water in a 100 mL volumetric flask. 40 mL acetonitrile was added. **The samples were ultrasonically treated** for 20 min, and diluted with purified water **to a** volume of 100 mL. Then, the samples of the 5 diuretics were injected into **the** HPLC **according to** the **above described** analytical method.

Results and Discussion

Optimization of analytical conditions

To establish a method for the simultaneous determination of five LDs by HPLC with DAD detection, **solutions of methanol/water, methanol/water** containing triethylamine or phosphoric acid, acetonitrile/water, **and** acetonitrile/water containing

phosphoric acid or triethylamine were first used to separate the compounds, but the selectivity between these five LDs was not optimal. Then, we chose a 0.05mol/L solution of potassium dihydrogen phosphate with acetonitrile, which provided a different selectivity than the other conditions and thus a better separation between the five LDs. Representative HPLC chromatograms for the simultaneous separation of the five LDs with different buffer pH or acetonitrile contents are shown in Fig 2 and Fig 3. The mobile phase composed of acetonitrile - 0.05mol/L of KH₂PO₄ (pH adjusted to 4.0 using diluted phosphoric acid) (36: 64, v/v) provided a short analysis time that did not exceed 25 min while maintaining acceptable resolution between compounds.

Method Validation

The linear range, precision, stability, and recovery results are showed in Tables 1 and 2. The linear range of all five LDs was wide and showed a good linear relationship ($r>0.999$). As shown, the precision was measured in two parts: intraday precision (with RSD values between 0.6% and 1.8%), and interday precision (with RSD values between 1.4% and 2.3%), which showed that the instrument had good precision. The RSD% of the peak areas for furosemide, torasemide, azosemide, bumetanide, and etacrynic acid for stability were 1.1%, 0.7%, 1.3%, 1.1%, and 0.5%, indicating that the sample solutions were stable over 8 h. The recovery results revealed average recovery rates from 97.2% to 102.1% % with an RSD<1.9%, indicating that the method had good accuracy. All of the above results show that the established methods were effective and reliable.

Qualitative investigation.

UV Spectral Similarity.

The similarity of the UV spectra is due to the chemical structure of compounds, and different compounds have different UV absorption spectra, which can be used to characterize the LD compounds. The original and first-order spectra, illustrating the similarities of the five diuretics are shown in Table 3-4, and the vector graph of the five diuretics is shown in Fig 4, which indicates that the first-order spectra after derivation show more characteristic details than the original spectra. The similarity of the UV spectra can be used for the qualitative identification of the five diuretics, which improves the accuracy and other characterization.

Relative retention time.

The HPLC methods used in the literature mostly use the retention time to carry out the qualitative analysis. In multicomponent qualitative analysis, heavy use of the reference substance increases the detection cost; in the detection process, the reference substance often cannot be rapidly obtained, and the retention time is affected by the instrument, brand of chromatographic column, column temperatures, and flow rates or pH of the mobile phase. In addition, the five LD compounds with similar chemical structures and physical properties are difficult to qualitatively investigate based on the retention time of the components. In this experiment, the RRTs were chosen as a qualitative analysis index, and their robustness was investigated. The robustness results of the RRTs for the five LDs are shown in Table 5. The results showed that the RRTs were not affected by different instruments, flow velocity, mobile phase volume, pH value or column temperature (RSD was less than 5.0%). In the same system, different HPLC columns gave RRTs with a RSD > 31.0%, which failed to satisfy the requirements of qualitative analysis. The differences between RRTs can mainly be attributed to different manufacturers, and are associated with the properties and preparation of packing materials. To this end, we herein restricted the conditional parameters and used spectral similarity and RRT as the double indicator to qualify the qualitative analysis.

Quantitative study of QAMS.

Inspired by the HPLC-based ESM analytical method, QAMS uses a single component as the internal standard to simultaneously quantitatively measure itself and other analytes by calculating relative correction factors (RCFs). In recent decades, the QAMS method has been widely used in the evaluation of a large number of Chinese herbal medicines [22-28], drugs [29] and drug impurities [31-32]. In this study, etacrynic acid was chosen as an internal reference to calculate the RCF of the other four diuretics. To evaluate the robustness of the RCF, the influence of the pH values of mobile phase, ratio and flow rates of the mobile phase, chromatographic column types, chromatographic column temperatures, and injection volumes were investigated. The RCFs of the five LDs are shown in Table 6. The results show that the RCF experiment is repeatable under different analytical conditions, which ensures that the QAMS method can be well applied to routine analysis.

Sample Analysis

The quantities of the five LD samples determined by HPLC-ESM and HPLC-QAMS are shown in Table 7. Comparative analysis indicated that there was no significant difference between HPLC-ESM and HPLC-QAMS (RSD values were < 3.0%), which shows that the above method is accurate and reliable.

Conclusion.

In this paper, a method for the simultaneous determination of five diuretic drugs by HPLC-ESM and HPLC-QAMS was developed. In the HPLC-QAMS process, etacrynic acid was used as an internal reference to calculate the relative correction factor of the other four diuretics, and the influencing factors such as different chromatographic columns, instruments, column temperatures, mobile phases and flow velocities were investigated. The above established method was successfully applied to the qualitative identification and quantitative analysis of five LDs. Because the QAMS analysis method can provide reliable results, save reference materials and shorten analysis time, it has great potential for an enhanced role in hospital-based quality control and qualitative identification and quantitative analysis of diuretics in other medicinal materials.

Abbreviations

LDs: Loop diuretics; HPLC: high performance liquid chromatography; QAMS: quantitative analysis of multiple components with a single marker; ESM: external standard method; RSD: relative standard deviation; RCFs: relative correction factors

Declarations

Ethics approval and consent to participate

Not Applicable.

Consent for publication

Not Applicable.

Availability of data and materials

The majority of the data used to support the findings of this study are included within the article. Other data are available from the corresponding author upon request.

Competing interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Funding

This study was financially supported by Technology Key Program of Shiyan, China (number 18Y73).

Authors' contributions

FCC and BXF provided the loop diuretics drugs and dosage forms, proposed the subject, analyze and interpret of the data, draft the article. PL and SCW designed the assay, conducted its validation, and participated in revision of the manuscript.

Acknowledgements

The authors acknowledged the support from Renmin hospital of Hubei University of Medicine.

Authors' information

Affiliations

Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei, 442008, P.R. China.

Fuchao Chen, Baoxia Fang, Peng Li

School of Pharmacy, Xi'an Jiaotong University, Xi'an, 710061, Shanxi, PR China.

Sicen Wang

References

1. Roush GC, Kaur R, Ernst ME (2014) Diuretics: a review and update. *J Cardiovasc Pharmacol Ther* 19: 5-13.
2. Wile D (2012) Diuretics: a review. *Ann Clin Biochem* 49: 419-431.
3. Anisman SD, Erickson SB, Morden NE (2019) How to prescribe loop diuretics in oedema. *BMJ* 364: 1359.

4. Ng KT, Jll Y (2018) Continuous infusion vs. intermittent bolus injection of furosemide in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials. *Anaesthesia* 73: 238-247.
5. Cosín J, Díez J (2002) Torasemide in chronic heart failure: results of the TORIC study. *Eur J Heart Fail* 4: 507-513.
6. Lykke K, Töllner K, Erker T (2015) Structure-activity relationships of bumetanide derivatives: correlation between diuretic activity in dogs and inhibition of the human NKCC2A transporter. *Brit J Pharmacol* 172: 4469-4480.
7. Alisky JM, Tuttle TF (2003) Ethacrynic acid can be effective for refractory congestive heart failure and ascites. *South Med J* 96: 1148-1150.
8. Hampel P, Römermann K, MacAulay N (2018) Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium- potassium-chloride- cotransporter human variants hNKCC1A and hNKCC1B. *Sci Rep* 8: 9877.
9. Zhang L, Wang RL, Tian Y (2015) Determination of torasemide in human plasma and its bioequivalence study by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. *J Pharm Anal* 6: 95-102.
10. Stolarczyk M, Hubicka U, Krzek J (2015) Simultaneous determination of eight hypotensive drugs of various chemical groups in pharmaceutical preparations by HPLC-DAD. *J AOAC Int* 98: 1542-1548.
11. Subramanian V, Nagappan K, Mannemala S (2015) Optimization and validation of a sensitive method for HPLC-PDA simultaneous determination of torasemide and spironolactone in human plasma using central composite design. *Acta Chim Slov* 62:63 3-641.
12. Legorburu M, Alonso RM, Ortiz E (2001) Quantitative determination of the loop diuretic bumetanide in urine and pharmaceuticals by high-performance liquid chromatography with amperometric detection. *J Chromatogr Sci* 39:425-530.
13. Lin CW, Gonzalez P, Yuan F (2011) Cellular pharmacokinetic and pharmacodynamic analyses of ethacrynic acid: implications in topical drug delivery in the eye. *Mol vis* 17: 2507-2515.
14. Lukáš Zahálka, Sylva Klovřzová, Ludmila Matysová, Zdenka Šklubalová, Petr Solich (2018) Furosemide ethanol-free oral solutions for paediatric use: formulation HPLC method and stability study. *Eur J Hosp Pharm* 25:144-149.
15. Naguib IA, Abdelaleem EA, Emam AA, Ali NW, Abdallah FF (2018) Development and validation of HPTLC and green HPLC methods for determination

of furosemide spironolactone and canrenone in pure forms tablets and spiked human plasma. *Biomed Chromatogr* 32(10): e4304.

16. Li J, Guo Z, Zhao X, Han P, Feng S (2015) Simultaneous determination of four drugs for kidney diseases in urine by high performance liquid chromatography. *Se pu* 33: 1210-1213.

17. Baranowska I, Płonka J (2016) Monitoring of biogenic amines and drugs of various therapeutic groups in urine samples with use of HPLC. *Biomed Chromatogr* 30: 652-657.

18. Baranowska I, Markowski P, Baranowski J (2009) Development and validation of an HPLC method for the simultaneous analysis of 23 selected drugs belonging to different therapeutic groups in human urine samples. *Anal Sci* 1307-1313.

19. Youm I, Youan BBC (2013) Validated reverse-phase high-performance liquid chromatography for quantification of furosemide in tablets and nanoparticles. *J Anal Methods Chem* 2013:1-9.

20. Zhang Z, Wang D, Zhang L, Du M, Chen G (2008) Determination of diuretics in human urine by hollow fiber-based liquid-liquid-liquid microextraction coupled to high performance liquid chromatography. *Analyst* 133:1187-1194.

21. Chen Y, Liu Y (2011) Analytical methods for the determination of anti-diuretic peptides in biological samples: challenges and perspectives. *Curr Anal Chem* 7: 117-129.

22. Huan Y, Jie Z, Shang XY, et al. (2018) Multi-component analysis of Ilex Kudingcha C. J. Tseng by a single marker quantification method and chemometric discrimination of HPLC fingerprints. *Molecules* 23: 854

23. Li Y, Zhang Y, Zhang Z, Hu Y, Cui X, Xiong Y (2019) Quality evaluation of Gastrodia Elata Tubers based on HPLC fingerprint analyses and quantitative analysis of multi-components by single marker. *Molecules* 24:1521.

24. Zhu C, Li X, Zhang B, Lin Z (2017) Quantitative analysis of multi- components by single marker-a rational method for the internal quality of Chinese herbal medicine. *Integr Med Res* 6:1-11.

25. Chen LH, Wu Y, Guan YM, Jin C, Zhu WF, Yang M (2018) Analysis of the high-performance liquid chromatography fingerprints and quantitative analysis of multicomponents by single marker of products of fermented cordyceps sinensis. *Comp Biochem Physiol* 17(3):799-803.

26. Wang S, Xu Y, Wang Y (2017) Simultaneous determination of six active

components in Oviductus Ranae via quantitative analysis of multicomponents by single marker. *J Anal Methods Chem* 2017: 9194847.

27. Wang CQ, Jia XH, Zhu S, Komatsu K, Wang X, Cai SQ (2015) A systematic study on the influencing parameters and improvement of quantitative analysis of multi-component with single marker method using notoginseng as research subject. *Talanta* 134:587-595.

28. Chen A, Sun L, Yuan H, Wu A, Lu J, Ma S (2017) A holistic strategy for quality and safety control of traditional Chinese medicines by the "iVarious" standard system. *J Pharm Anal* 7(5):271-279.

29. Chen FC, He XD, Fang BX, Wang SC (2020) Simultaneous quantitative analysis of six proton-pump inhibitors with a single marker and evaluation of stability of investigated drugs in polypropylene syringes for continuous infusion use. *Drug Des Dev Ther* 14: 5689-5698.

30. International Conference on Harmonization (2005), Q2 (R1): Validation of analytical procedures: text and methodology, ICH, Geneva, Switzerland.


31. Guo Q, Liu L, Zhou ZG, Qin Y (2019) Content determination of 7 related substances in solifenacin succinate raw material by HPLC with principal component self-control with correction factor. *China Pharm* 30(11):1481-1486.

32. Yang QJ, Wang H, Gao YJ, Li JQ, Jiao JD, Quan QB, Chen JQ (2015) Application of substitution method of reference substance in the rapid determination of sedative drugs by HPLC. *Chin J Mod Appl Pharm* 32(11):1376-1381.


Figure legends

Figure 1.


Chemical structures of furosemide (a), torasemide (b), azosemide (c), bumetanide (d) and etacrynic acid (e).




(a)




(b)



(c)



(d)



(e)

Figure 2.

A typical chromatogram of standard drug mixture samples. Chromatographic conditions were acetonitrile-0.05 mol·L⁻¹ potassium dihydrogen phosphate (36: 64, v/v); the buffer pH was varied. a. pH 3.0; b. pH 3.5; c. pH 4.0; d. pH 4.5; e. pH 5.0.




Figure 3.

A typical chromatogram of standard drug mixture samples. Chromatographic conditions were acetonitrile-0.05 mol·L⁻¹ potassium dihydrogen phosphate (phosphoric acid to adjust pH to 4.0); the acetonitrile content was varied. a. acetonitrile content 30; b. acetonitrile content 34; c. acetonitrile content 36; d. acetonitrile content 38; e. acetonitrile content 40.




Figure 4.

UV spectra and 1st UV spectra of furosemide, torasemide, azosemide, bumetanide and etacrynic acid.




Table 1 Regression equation, correlation coefficient (r), linear range and detection limit of the five diuretic drugs

Studied drug	Regression Equation	r	(Linear Range) / ($\mu\text{g}\cdot\text{mL}^{-1}$)	(Detection Limit) /$\mu\text{g}\cdot\text{mL}^{-1}$
Etacrynic acid	$y=20.301x-1.624$	0.9993	2.5-150	0.25
Torsemide	$y=33.204x+3.131$	0.9998	2.5-150	0.08
Furosemide	$y=27.634x-0.970$	0.9999	2.5-150	0.05
Azosemide	$y=43.381x+8.666$	0.9992	2.5-150	0.13
Bumetanide	$y=36.124x+1.320$	0.9999	2.5-150	0.20

Table 2 Recovery test of the developed HPLC analysis method

Studied drug	Measured concentrations (µg/mL)	Accuracy %	Average recovery (%)	RSD (%)
Etacrynic acid	40.0	98.3		
	50.0	97.7	98.8	1.4
	60.0	100.4		
Torasemide	40.0	96.7		
	50.0	99.1	98.5	1.6
	60.0	99.6		
Furosemide	40.0	100.6		
	50.0	102.1	100.3	1.9
	60.0	98.3		
Azosemide	40.0	97.2		
	50.0	98.2	97.9	0.7
	60.0	98.4		
Bumetanide	40.0	97.5		
	50.0	100.8	99.3	1.7
	60.0	99.6		

Table 3 UV spectra similarity of the five diuretic drugs

Studied drug	Torasemide	Furosemide	Azosemide	Etacrynic acid	Bumetanide
Torasemide	1.0000				
Furosemide	0.7494	1.0000			
Azosemide	0.6574	0.8550	1.0000		
Etacrynic acid	0.9219	0.7761	0.6553	1.0000	
Bumetanide	0.8965	0.8499	0.7544	0.9451	1.0000

Table 4 1st UV spectra similarity of the five diuretic drugs

Studied drug	Torasemide	Furosemide	Azosemide	Etacrynic acid	Bumetanide
Torasemide	1.0000				
Furosemide	-0.1078	1.0000			
Azosemide	-0.1712	0.1698	1.0000		
Etacrynic acid	0.8132	0.0873	-0.0475	1.0000	
Bumetanide	0.3288	0.3369	0.0457	0.1218	1.0000

Table 5 Effects of different instruments, columns, column temperatures, flow rates, volume and pH on RRTs (n = 3)

Effects Factor	Torasemide	Furosemide	Azosemide	Etacrynic acid	Bumetanide
Chromatographic Columns	38.95	36.77	35.97	-	31.67
HPLC Instruments	1.09	1.24	3.38	-	2.34
RSD% Column Temperatures	1.58	1.36	0.54	-	0.93
Flow Volume of Mobile Phase	2.10	2.11	0.93	-	1.22
Flow Rate of Mobile Phase	1.22	0.75	0.40	-	0.005
pH Value of Mobile Phase	4.87	3.21	3.99	-	3.71
$\bar{\chi}$	0.31	0.49	0.63	-	2.11
S	0.001	0.001	0.001	-	0.009
$\bar{\chi}\pm 3S$	0.31±0.003	0.49±0.004	0.63±0.002	-	2.11±0.028


Table 6 Relative correction factor of the five diuretic drugs

Studied drug	Wavelength	RSD/%	Relative Correction
	(nm)		Factor
Etacrynic acid	277	-	1
Toraseamide	292	0.18	0.3232
Furosemide	334	0.35	0.9024
Azosemide	326	0.63	0.8064
Bumetanide	260	0.67	0.5566


Table 7 Results of the comparison of the five diuretic drugs

Studied drug	the QAMS Methods		the ESM Methods	
	Accuracy	RSD	Accuracy	RSD
	(%)	(%)	(%)	(%)
Etacrynic acid tablet	95.1	2.1	96.2	1.9
Toraseamide injection	97.4	1.3	96.8	1.4
Furosemide injection	103.2	0.7	102.9	1.0
Azosemide tablet	98.5	1.8	99.1	2.2
Bumetanide injection	102.4	1.6	101.6	1.4


Figures




(a)




(b)



(c)



(d)



(e)

Figure 1

Chemical structures of furosemide (a), torasemide (b), azosemide (c), bumetanide (d) and etacrynic acid (e).




Figure 2

A typical chromatogram of standard drug mixture samples. Chromatographic conditions were acetonitrile-0.05 mol·L⁻¹ potassium dihydrogen phosphate (36: 64, v/v); the buffer pH was varied. a. pH 3.0; b. pH 3.5; c. pH 4.0; d. pH 4.5; d. pH 5.0.




Figure 3

A typical chromatogram of standard drug mixture samples. Chromatographic conditions were acetonitrile-0.05 mol·L⁻¹ potassium dihydrogen phosphate (phosphoric acid to adjust pH to 4.0); the

acetonitrile content was varied. a. acetonitrile content 30; b. acetonitrile content 34; c. acetonitrile content 36; d. acetonitrile content 38; e. acetonitrile content 40.




Figure 4

UV spectra and 1st UV spectra of furosemide, torasemide, azosemide, bumetanide and etacrynic acid.